674 results on '"Bunin, Nancy"'
Search Results
2. Effect of rabbit ATG PK on outcomes after TCR-αβ/CD19–depleted pediatric haploidentical HCT for hematologic malignancy
3. Genotype, oxidase status, and preceding infection or autoinflammation do not affect allogeneic HCT outcomes for CGD
4. Infections in Infants with SCID: Isolation, Infection Screening, and Prophylaxis in PIDTC Centers.
5. 50 Utilizing an Ethical Lens to Assess a Series of Patients With X-Linked CGD Who Did Not Undergo Hematopoietic Stem Cell Transplant
6. 106 Outcomes Following Hematopoietic Cell Transplant for CD3δ Severe Combined Immune Deficiency: a PIDTC Natural History Study
7. KIR-favorable TCR-αβ/CD19-depleted haploidentical HCT in children with ALL/AML/MDS: primary analysis of the PTCTC ONC1401 trial
8. Higher Risks of Toxicity and Incomplete Recovery in 13- to 17-Year-Old Females after Marrow Donation: RDSafe Peds Results.
9. Effect of Aging and Predonation Comorbidities on the Related Peripheral Blood Stem Cell Donor Experience: Report from the Related Donor Safety Study.
10. Variables affecting outcomes after allogeneic hematopoietic stem cell transplant for cerebral adrenoleukodystrophy
11. Unrelated donor α/β T cell– and B cell–depleted HSCT for the treatment of pediatric acute leukemia
12. Reduced-Intensity/Reduced-Toxicity Conditioning Approaches Are Tolerated in XIAP Deficiency but Patients Fare Poorly with Acute GVHD
13. Tabelecleucel for EBV+ PTLD following allogeneic HCT or SOT in a multicenter expanded access protocol
14. Pilot Study of Unrelated Donor (URD) Peripheral Stem Cell Transplant (PSCT) with CD45RA-Depleted Addback Following TCRab/CD19 Depletion in Pediatric Patients with Hematologic Malignancies
15. Outcomes Following Matched Sibling Donor Transplant for Severe Combined Immunodeficiency: A Report from the Pidtc
16. Optimal Rabbit Antithymocyte Pharmacokinetics (PK) Is Associated with Improved Disease-Free Survival (DFS) in TCR-Αβ/CD19-Depleted Pediatric Haploidentical Hematopoietic Cell Transplantation for Hematologic Malignancies
17. Outcomes of Unrelated Partial T Cell Depleted Stem Cell Transplantation for Patients with Hemoglobinopathies
18. Unrelated and Haploidentical Peripheral Stem Cell Transplant with Tcrαβ/CD19 Depletion for the Treatment of Pediatric Patients with Inborn Errors of Immunity
19. Adenoviral Cellular Therapy with Adenovirus (ADV)-Specific Cytotoxic T-Lymphocytes (CTLs) for Resistant Infections in Children, Adolescent, and Young Adult (CAYA) Patients Following Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT): A Promising Approach
20. Immune Dysregulation in Human ITCH Deficiency Successfully Treated with Hematopoietic Cell Transplantation
21. Long-term outcomes of 176 patients with X-linked hyper-IgM syndrome treated with or without hematopoietic cell transplantation.
22. Quality Improvement Initiative to Improve Time and Adherence to Revaccination after Hematopoietic Cell Transplantation: Implementation of a Revaccination Clinic within the Transplantation Program
23. Hematopoietic Stem Cell Transplantation Successfully Treats CD40LG Duplication
24. Acute Kidney Injury in Children after Hematopoietic Cell Transplantation Is Associated with Elevated Urine CXCL10 and CXCL9
25. Partially CD3+-Depleted Unrelated and Haploidentical Donor Peripheral Stem Cell Transplantation Has Favorable Graft-versus-Host Disease and Survival Rates in Pediatric Hematologic Malignancy
26. 47 Attention and Working Memory (WM) in Pediatric Patients Prior to Hemopoietic Stem Cell Transplant (HSCT) for Hematologic Malignancies
27. Phase II/III trial of a pre‐transplant farnesyl transferase inhibitor in juvenile myelomonocytic leukemia: A report from the Children's Oncology Group
28. Correction to: Infections in Infants with SCID: Isolation, Infection Screening and Prophylaxis in PIDTC Centers
29. The Hematopoietic Cell Transplant Comorbidity Index predicts survival after allogeneic transplant for nonmalignant diseases
30. Tabelecleucel for EBV+PTLD after allogeneic HCT or SOT in a multicenter expanded access protocol
31. One-Unit versus Two-Unit Cord-Blood Transplantation for Hematologic Cancers
32. Comparison of outcomes of hematopoietic stem cell transplantation without chemotherapy conditioning by using matched sibling and unrelated donors for treatment of severe combined immunodeficiency
33. Neurocognitive Dysfunction in Hematopoietic Cell Transplant Recipients: Expert Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Complications and Quality of Life Working Party of the European Society for Blood and Marrow Transplantation
34. Germline CBL mutations cause developmental abnormalities and predispose to juvenile myelomonocytic leukemia.
35. Treatment of Omenn syndrome using multiple immunosuppressive strategies: a case series
36. Hematopoietic Stem Cell Transplantation
37. The role of peritoneal drainage in veno-occlusive disease in pediatric patients post hematopoietic stem cell transplant
38. Neurocognitive dysfunction in hematopoietic cell transplant recipients: expert review from the late effects and Quality of Life Working Committee of the CIBMTR and complications and Quality of Life Working Party of the EBMT
39. Immune Reconstitution Following TCRαβ/CD19-Depleted Hematopoietic Cell Transplantation for Hematologic Malignancy in Pediatric Patients
40. Monogenic early-onset lymphoproliferation and autoimmunity: Natural history of STAT3 gain-of-function syndrome
41. Late Survival after Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease in a Single-Center Cohort
42. Safety and Efficacy of Virus-Specific Cytotoxic T-Lymphocytes Manufactured By the IFN-γ Cytokine Capture System for the Treatment of Refractory Adenovirus, Cytomegalovirus, Epstein Barr Virus, and BK Virus Infections in Children, Adolescents and Young Adults after Allogeneic Hematopoietic Stem Cell Transplantation, Solid Organ Transplantation, or with Primary Immunodeficiency (IND# 17449)
43. Allogenic Hematopoietic Cell Transplantations Are Effective in Patients with p47phox Chronic Granulomatous Disease: A Primary Immune Deficiency Treatment Consortium Study
44. Manufacture, Immunological Characterization and Clinical Response of GMP Grade Sars-COV-2 Cytotoxic T Lymphocytes (CTLs) Utilizing the Clinimacs® Cytokine Capture System
45. Adoptive immunotherapy for primary immunodeficiency disorders with virus-specific T lymphocytes
46. IgH-V(D)J NGS-MRD measurement pre- and early post-allotransplant defines very low- and very high-risk ALL patients
47. Manufacture and Characterization of Good Manufacturing Practice-Compliant SARS-COV-2 Cytotoxic T Lymphocytes
48. Updated Efficacy and Safety of Tabelecleucel in Patients with Epstein-Barr Virus-Positive (EBV+) Leiomyosarcomas (LMS)
49. Effect of body mass in children with hematologic malignancies undergoing allogeneic bone marrow transplantation
50. The addition of sirolimus to tacrolimus/methotrexate GVHD prophylaxis in children with ALL: a phase 3 Children's Oncology Group/Pediatric Blood and Marrow Transplant Consortium trial
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.